Wells Fargo Reiterates Overweight Rating on Nurix (NRIX)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. ANT
3. SPY
4. META
5. FFAI
6. FFR
7. CART
8. LLY
9. TSLA
10. FICO

Go back to Wells Fargo Reiterates Overweight Rating on Nurix (NRIX)

Nurix Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Provides a Corporate Update

October 11, 2024 4:00 PM EDT

Initiated Phase 1b dose expansion of NX-5948 in chronic lymphocytic leukemia patient population with Fast Track Designation from the FDA

Initiated Phase 1b dose expansion of NX-5948 in Waldenstroms macroglobulinemia, follicular lymphoma and marginal zone lymphoma patients

Reinitiated enrollment for NX-2127 in a Phase 1a/b trial in oncology

Presented preclinical data on Degrader-Antibody Conjugates (DACs), a new class of therapeutics

Well capitalized with cash and marketable securities of $457.5 million

SAN FRANCISCO, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Nurix... More